
Axsome Therapeutics Inc (NASDAQ:AXSM) shares are trading higher Tuesday after the company announced it received and agreed to Postmarketing Requirements/Commitments proposed by the U.S. Food and Drug Administration with respect to the New Drug Application (NDA) for its AXS-05.
AXS-05 is Axsome's product candidate for the treatment of major depressive disorder. The company anticipates potential FDA action on the NDA sometime in the second quarter.